Moderna: positive data against propionic acidemia
(CercleFinance.com) - Moderna today presented interim results from the Phase 1/2 clinical trial of mRNA-3927, an investigational mRNA-based therapy for propionic acidemia (PA), at the American Society of Gene + Cell Therapy (ASGCT) 2023 Annual Meeting.
The ongoing global Phase 1/2 clinical trial is an open-label, multi-center study designed to evaluate the safety, pharmacodynamics and pharmacokinetics of mRNA-3927 in participants aged one year and older with genetically confirmed PA.
mRNA-3927 was well tolerated at the doses administered, with encouraging early evidence of dose-dependent pharmacology and potential clinical benefit.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
The ongoing global Phase 1/2 clinical trial is an open-label, multi-center study designed to evaluate the safety, pharmacodynamics and pharmacokinetics of mRNA-3927 in participants aged one year and older with genetically confirmed PA.
mRNA-3927 was well tolerated at the doses administered, with encouraging early evidence of dose-dependent pharmacology and potential clinical benefit.
Copyright (c) 2023 CercleFinance.com. All rights reserved.